New drug MK-2828 tested in kidney patients – first look at dosing

NCT ID NCT07348237

Recruiting now Knowledge-focused Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This early-stage study is testing a single dose of the drug MK-2828 in 24 people with different levels of kidney function, including those with severe kidney failure or on dialysis. The goal is to measure how the drug moves through the body over time and compare it to healthy volunteers. No treatment benefit is expected; the results will guide future dosing recommendations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MK-2828
What this could lead to: If successful, this study will help doctors understand how to dose MK-2828 safely for people with kidney problems.
What could go wrong: This is a very early, small Phase 1 trial focused on drug levels, not on treating disease. It may not lead to any treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY FAILURE END-STAGE RENAL DISEASE RENAL IMPAIRMENT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Floridian Clinical Research ( Site 0001)
RECRUITING

Miami Lakes, Florida, 33016, United States
Orlando Clinical Research Center ( Site 0002)
RECRUITING

Orlando, Florida, 32809, United States
Panax Clinical Research ( Site 0003)
RECRUITING

Miami Lakes, Florida, 33014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.